Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Molecular Biomarkers in Non-Hodgkin and Hodgkin Lymphomas
share announcement

Molecular Biomarkers in Non-Hodgkin and Hodgkin Lymphomas

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 5469

Special Issue Editor

Dr. Lara Mussolin

E-Mail Website
Guest Editor
1. Maternal and Child Health Department, Padua University, 35128 Padua, Italy
2. Istituto di Ricerca Pediatrica Città della Speranza, 35127 Padua, Italy
Interests: analysis of molecular prognostic markers in pediatric non-Hodgkin lymphoma and pediatric Hodgkin lymphoma; minimal residual disease study; new therapeutic targets; liquid biopsy; multi-omics data approaches

Special Issue Information

Dear Colleagues,

Advances in the field of lymphomas allowed, in the 2016 WHO classification update, incorporating new scientific and clinical information to refine diagnostic criteria and, in some cases, change nomenclature of the disease and introduce newly recognized disease entities. Lymphomas are a group of hematological malignancies derived from lymphocytes, clinically and biologically heterogeneous with overlapping diagnostic features. Additionally, patients’ risk stratification based on recently identified molecular risk categories is useful for improving therapies, increasing survival for high-risk patients, and decreasing toxicity for low-risk patients. Indeed, much has been learned about minimal disseminated disease and minimal residual disease in specific lymphoma subtypes. Today, the availability of high-throughput techniques represents essential tools to detect new molecular alterations, ranging from those involving the DNA, RNA, microRNAs (miRNAs), and proteins, which can serve as diagnostic markers and targets for personalized medicine.

This Special Issue aims to present original research and review articles that summarize the state of the art, deal with open questions, and cover current aspects of molecular biomarker discovery for Hodgkin and Non-Hodgkin lymphomas. On behalf of the Editorial Office, I would like to invite you to contribute your review articles and research papers concerning "Molecular Biomarkers in Non-Hodgkin and Hodgkin Lymphomas" for peer review and possible publication.

Dr. Lara Mussolin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hodgkin lymphoma
  • non-hodgkin lymphoma
  • molecular markers
  • risk factors
  • omics data
  • comparative analyses of primary tumor, relapse
  • therapeuthic targets

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

7 pages, 750 KiB  
Article
Lack of Association between Chlamydophila psittaci and Ocular Adnexal MALT Lymphoma in Korean Patients—Is the Geographic or Genetic Difference Significant?
by Uiju Cho, Inju Cho, Sung Hak Lee, Suk Woo Yang, Seok Goo Cho, Youn Soo Lee, Hye Won Lee and Gyeongsin Park
Diagnostics 2021, 11(11), 2069; https://doi.org/10.3390/diagnostics11112069 - 9 Nov 2021
Cited by 3 | Viewed by 1461
Abstract
Clamydophila psittaci (C. psittaci) has been proposed to be an etiologic factor in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the ocular adnexa. However, the pathogenetical significance of the infection has not been fully elucidated. Many previous [...] Read more.
Clamydophila psittaci (C. psittaci) has been proposed to be an etiologic factor in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the ocular adnexa. However, the pathogenetical significance of the infection has not been fully elucidated. Many previous studies have shown controversial results regarding C. psittaci detection rates in said patients, ranging from 0 to 87%. We investigated the presence of C. psittaci in a single institutional cohort (n = 150) of ocular adnexal MALT lymphoma (OAML) patients in Korea. We tried to exclude the methodological biases derived from the different primer sets in polymerase chain reaction-based studies. For that reason, we applied five sets of primers, including four previously reported and one newly designed primer set. There was no case of C. psittaci-positive OAML in repeated trials validated with appropriate positive and negative controls. All 150 cases showed negative results with five primer sets. These results suggest that the pathogenetic role of C. psittaci in ocular adnexal MALT lymphoma might have been overestimated to date, at least in the Korean population. Therefore, the molecular diagnosis of C. psittaci is considered a very low priority. Full article
(This article belongs to the Special Issue Molecular Biomarkers in Non-Hodgkin and Hodgkin Lymphomas)
►▼ Show Figures

Figure 1

22 pages, 4630 KiB  
Article
Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence
by Ombretta Repetto, Federica Lovisa, Caterina Elia, Daniel Enderle, Filippo Romanato, Salvatore Buffardi, Alessandra Sala, Marta Pillon, Agostino Steffan, Roberta Burnelli, Lara Mussolin, Maurizio Mascarin and Valli De Re
Diagnostics 2021, 11(6), 917; https://doi.org/10.3390/diagnostics11060917 - 21 May 2021
Cited by 15 | Viewed by 3303
Abstract
Exosomes and other small extracellular vesicles (EVs) are potential sources of cancer biomarkers. Plasma-derived EVs have not yet been studied in pediatric Hodgkin lymphoma (HL), for which predictive biomarkers of relapse are greatly needed. In this two-part proteomic study, we used two-dimensional difference [...] Read more.
Exosomes and other small extracellular vesicles (EVs) are potential sources of cancer biomarkers. Plasma-derived EVs have not yet been studied in pediatric Hodgkin lymphoma (HL), for which predictive biomarkers of relapse are greatly needed. In this two-part proteomic study, we used two-dimensional difference gel electrophoresis (2D-DIGE) followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) to analyze EV proteins of plasma collected at diagnosis from children with nodular sclerosis HL, relapsed or not. EVs isolated using membrane affinity had radii ranging from 20 to 130 nm and contained the programmed cell death 6-interacting (ALIX) and the tumor susceptibility gene 101 (TSG101) proteins, whereas calnexin (CANX) was not detected. 2D-DIGE identified 16 spots as differentially abundant between non-relapsed and relapsed HL (|fold change| ≥ 1.5, p < 0.05). LC–MS/MS identified these spots as 11 unique proteins, including five more abundant in non-relapsed HL (e.g., complement C4b, C4B; fibrinogen γ chain, FGG) and six more abundant in relapsed HL (e.g., transthyretin, TTR). Shotgun LC–MS/MS on pooled EV proteins from non-relapsed HL identified 161 proteins, including 127 already identified in human exosomes (ExoCarta data). This EV cargo included 89 proteins not yet identified in exosomes from healthy plasma. Functional interrogation by the Database for Annotation, Visualization and Integrated Discovery (DAVID) revealed that the EV proteins participate in platelet degranulation and serine-type endopeptidase activity as the most significant Gene Ontology (GO) biological process and molecular function (p < 0.01). Full article
(This article belongs to the Special Issue Molecular Biomarkers in Non-Hodgkin and Hodgkin Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop